When is Daratumumab's Patent Expiry?
Daratumumab, marketed as Darzalex and Darzalex Faspro, is currently protected by several patents. The earliest key patents for daratumumab are expected to expire in 2027 and 2029 [1]. However, the patent landscape for drugs is complex, and further patent filings and extensions can alter these timelines [1].
What Does Patent Expiry Mean for Daratumumab?
Once patents expire, other companies may be able to develop and market generic or biosimilar versions of daratumumab [2]. This typically leads to increased competition and a reduction in drug prices [2]. For daratumumab, this would mean the potential for biosimilar versions to become available after the expiration of its primary patents [1].
How Are Daratumumab Patents Being Challenged?
Patent challenges can arise from companies seeking to introduce generic or biosimilar alternatives to the market sooner [3]. These challenges often involve legal proceedings that can determine the validity or infringement of existing patents [3]. Details regarding specific challenges to daratumumab's patents are subject to ongoing legal processes.
What is the Difference Between Generic and Biosimilar Drugs?
Generic drugs are chemically identical to their brand-name counterparts. Biosimilars, on the other hand, are highly similar to an approved biologic product (the reference product), with no clinically meaningful differences in terms of safety, purity, and potency [4]. Daratumumab is a biologic, so any future alternatives would be biosimilars [4].
Who is Developing Potential Daratumumab Biosimilars?
Several companies are actively developing biosimilars for biologic drugs, and some are likely to be pursuing biosimilars for daratumumab [2][5]. These include major pharmaceutical companies with established biosimilar divisions.
What is the Timeline for Daratumumab Biosimilar Entry?
The entry of biosimilars depends on the expiry of daratumumab's patents and the successful navigation of the regulatory approval process [1][4]. While early patent expiries are noted for 2027 and 2029, actual market entry could be influenced by patent litigation and the time required for biosimilar development and FDA review [1][4].
What Clinical Data Supports Daratumumab's Efficacy?
Daratumumab has demonstrated significant efficacy in treating multiple myeloma and systemic light chain amyloidosis. Clinical trials have shown improved progression-free survival and overall survival in patients treated with daratumumab in combination with other therapies [6][7]. Specific data can be found in the prescribing information and published clinical studies [6][7].
What Are the Key Competitors to Daratumumab?
Daratumumab competes with other novel agents used in multiple myeloma treatment. These include other monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs. Examples of competitors include isatuximab (Sarclisa), lenalidomide (Revlimid), and bortezomib (Velcade) [8].
What is the Cost of Daratumumab?
The cost of daratumumab can be substantial, reflecting its status as a novel biologic therapy. Pricing varies based on dosage, administration route (intravenous or subcutaneous), and geographic region. Patient assistance programs are often available to help offset costs [9].
Where Can I Find More Information on Daratumumab Patents?
For detailed information on drug patents, including those for daratumumab, DrugPatentWatch.com offers a comprehensive database and analysis of patent expiry dates and related intellectual property [1].
---
Sources
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration (FDA) - Biosimilar Medicines
[3] U.S. Food and Drug Administration (FDA) - What are biosimilars?
[4] U.S. Food and Drug Administration (FDA) - Promoting Development of Biosimilar and Interchangeable Biological Products
[5] Pharmaceutical companies' pipeline reports
[6] Clinical trial data for daratumumab (e.g., POLLUX, SIRIUS-MM, GEN501)
[7] Prescribing Information for Darzalex and Darzalex Faspro
[8] Market analysis reports for multiple myeloma treatments
[9] Pharmacy benefit manager websites and drug pricing databases